医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Prana’s PBT434 Lowers Alpha-Synuclein and Prevents Neurodegeneration

2017年07月05日 PM10:00
このエントリーをはてなブックマークに追加


 

MELBOURNE, Australia & SAN FRANCISCO

Prana Biotechnology Ltd (NASDAQ: PRAN) (ASX: PBT) today announced the article “The novel compound PBT434 prevents iron-mediated neurodegeneration and alpha-synuclein toxicity in multiple models of Parkinson’s disease” was accepted for publication in the peer reviewed journal Acta Neuropathologica Communications. The peer reviewed article can be accessed from: https://actaneurocomms.biomedcentral.com/articles/10.1186/s40478-017-0456-2

The publication is the culmination of ten years of research from scientists at the Florey Institute of Neuroscience and Mental Health, (Melbourne, Australia), investigating compounds from Prana Biotechnology’s propriety chemical library. The novel drug candidate PBT434 is the first of a new generation of small molecules from the quinazolinone class of drugs that was specifically designed to block the accumulation and aggregation of alpha-synuclein, an abundant brain protein widely believed to be involved in the pathogenesis of Parkinson’s disease and related disorders.

Not only was PBT434 shown to block alpha-synuclein accumulation, but it also prevented loss of nerve cells in the region of the brain primarily affected in Parkinson’s disease, called the substantia nigra. To investigate the therapeutic potential of PBT434 to slow neurodegeneration, the researchers performed extensive animal testing in multiple Parkinson’s disease models, including tests in mice that over-expressed the alpha-synuclein protein. These results showed that PBT434 lowered alpha-synuclein and its toxic effects and simultaneously improved motor performance.

If these findings are also observed in patients with diseases caused by alpha-synuclein, PBT434 could address a significant unmet medical need in preventing their progression.

The key findings from the publication in Acta Neuropathologica Communications are:

  1. PBT434 prevents the formation of toxic alpha synuclein fibrils.
  2. PBT434 prevents the formation of insoluble alpha synuclein in animals.
  3. PBT434 prevents alpha synuclein mediated oxidative stress that induces cell death.
  4. PBT434 protects against cell death and preserves neuronal circuitry in both transgenic and toxin mouse models of Parkinson’s disease.
  5. PBT434 improves motor behaviour in Parkinson’s disease mouse models.
  6. PBT434 normalises brain iron distribution.

David Stamler, M.D., Prana’s Chief Medical Officer and Senior Vice President, Clinical Development said: “These findings are important because Parkinson’s disease and the related synucleinopathies cause significant disability and diminish the independence of afflicted individuals. An agent which slows disease progression could have a great impact on reducing disease burden and improving quality of life. We are eager to begin clinical testing of PBT434.”

The required animal testing has been completed and PBT434 is expected to begin human testing in a Phase 1 trial later this year.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170705005087/en/

CONTACT

Investor Relations
WE Buchan
Rebecca Wilson, +61 3 9866
4722
rwilson@buchanwe.com.au
Media
WE
Buchan
Scott Newstead, +61 3 9866 4722
snewstead@buchanwe.com.au

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • SCIEX and NUS Faculty of Science Announce Plans to Launch New Training Centre for Proteomics and Mass Spectrometry Across Asia Pacific
  • Puma Biotechnology and Specialised Therapeutics Asia Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in Australia, New Zealand and South East Asia
  • Preceptis Medical宣布面向中国的B轮融资和全球增长战略
  • オクタファルマ、開発途上国の血友病患者を治療するために当社のNuwiq製剤3050万国際単位を寄付
  • Octapharma捐赠3050万国际单位该公司药品 Nuwiq以治疗发展中国家的血友病患者